The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Imiquimod: mode of action
Abstract
OBJECTIVE: Since imiquimod, a nucleoside analogue of the imidazoquinoline family, has shown efficacy against many tumour entities, its mode of action has become a focus of scientific interest. RESULTS: The major biologic effects of imiquimod are mediated through agonistic activity towards toll-like receptors (TLR) 7 and 8, and consecutively, activation of nuclear factor-kappa B (NF-kappaB). The result of this activity is the induction of pro-inflammatory cytokines, chemokines and other mediators leading to activation of antigen-presenting cells and other components of innate immunity and, eventually, the mounting of a profound T-helper (Th1)-weighted antitumoral cellular immune response. Several secondary effects on the molecular and cellular level may also be explained, at least in part, by the activation of NF-kappaB. Moreover, independent of TLR-7 and TLR-8, imiquimod appears to interfere with adenosine receptor signalling pathways, and the compound causes receptor-independent reduction of adenylyl cyclase activity. This novel mechanism may augment the pro-inflammatory activity of the compound through suppression of a negative regulatory feedback mechanism which normally limits inflammatory responses. Finally, imiquimod induces apoptosis of tumour cells at higher concentrations. The pro-apoptotic activity of imiquimod involves caspase activation and appears to depend on B cell lymphoma/leukemia protein (Bcl)-2 proteins. CONCLUSIONS: Overall, imiquimod acts on several levels, which appear to synergistically underlie the profound antitumoral activity of the compound.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Integrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350
Cryns, V., & Yuan, J. (1998) · Genes & Development · doi:10.1101/gad.12.11.1551 · Cited by 1,228
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
Toll-like receptor function and signaling
Kaisho, T., & Akira, S. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.023 · Cited by 898
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Stanley, M. A. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01151.x · Cited by 377
Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Loré, K., Betts, M. R., Brenchley, J. M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, R. A., & Koup, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4320 · Cited by 291
Suzuki, H., Wang, B., Shivji, G. M., Toto, P., Amerio, P., Sauder, D. N., Tomai, M. A., & Miller, R. L. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00833.x · Cited by 284
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Old Meets New: The Interaction Between Innate and Adaptive Immunity
Clark, R., & Kupper, T. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23856.x · Cited by 214
Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, C. C., Moskaluk, C. A., Marini, M., Sugawara, K., Kozaiwa, K., Otaka, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.032 · Cited by 205
Prins, R. M., Craft, N., Bruhn, K. W., Khan-Farooqi, H., Koya, R. C., Stripecke, R., Miller, J. F., & Liau, L. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.157 · Cited by 203
Palamara, F., Meindl, S., Holcmann, M., Lührs, P., Stingl, G., & Sibilia, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3051 · Cited by 201
Imiquimod and resiquimod as novel immunomodulators
Dockrell, D. H. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.751 · Cited by 185
Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G., & Gilliet, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji207 · Cited by 182
Opposing actions of STAT-1 and STAT-3
Stephanou, A., & Latchman, D. S. (2005) · Growth Factors · doi:10.1080/08977190500178745 · Cited by 173
Role of Toll‐like receptors in costimulating cytotoxic T cell responses
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 171
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Sidky, Y. A., Borden, E. C., Weeks, C. E., et al. (1992) · PubMed · Cited by 169
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Schön, M. P., Schön, M., & Klotz, K.-N. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700286 · Cited by 164
Self-citationCutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod
Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H., & Radsak, M. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2476 · Cited by 164
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Gorski, K. S., Waller, E. L., Bjornton-Severson, J., Hanten, J. A., Riter, C. L., Kieper, W. C., Gorden, K. B., Miller, J. S., Vasilakos, J. P., Tomai, M. A., et al. (2006) · International Immunology · doi:10.1093/intimm/dxl046 · Cited by 158
Harrison, C. J., Jenski, L. J., Voychehovski, T., & Bernstein, D. I. (1988) · Antiviral Research · doi:10.1016/0166-3542(88)90032-0 · Cited by 154
Imiquimod 5 percent cream and the treatment of cutaneous malignancy
Navi, D., & Huntley, A. C. (2004) · Dermatology Online Journal · doi:10.5070/d34vw339w4 · Cited by 146
Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo
Urosevic, M., Maier, T., Benninghoff, B., Slade, H. B., Burg, G., & Dummer, R. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.10.1325 · Cited by 145
Megyeri, K., Au, W.-C., ROSZTÓCZY, I., Raj, N. B. K., Miller, R. L., Tomai, M. A., & Pitha, P. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2207 · Cited by 139
Schön, M. P., Wienrich, B. G., Drewniok, C., Bong, A. B., Eberle, J., Geilen, C. C., Gollnick, H. P. M., & Schön, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22528.x · Cited by 138
Self-citationBurns, R. P., Ferbel, B., Tomai, M. A., Miller, R. L., & Gaspari, A. A. (2000) · Clinical Immunology · doi:10.1006/clim.1999.4804 · Cited by 129
The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B Lymphocytes
Tomai, M. A., Imbertson, L. M., Stanczak, T. L., Tygrett, L. T., & Waldschmidt, T. J. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1673 · Cited by 126
Shackleton, M. J., Davis, I. D., Hopkins, W., Jackson, H. M., Dimopoulos, N., Tai, T. Y., Chen, Q., Parente, P., Jefford, M., Masterman, K., et al. (2004) · PubMed · Cited by 122
Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod
Schön, M. P., & Schön, M. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000025805.55340.c3 · Cited by 122
Self-citationGerster, J. F., Lindstrom, K. J., Miller, R. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049211v · Cited by 119
Thomsen, L. L., Topley, P., Daly, M. G., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.09.052 · Cited by 109
Imiquimod-Induced Interleukin-1α Stimulation Improves Barrier Homeostasis in Aged Murine Epidermis
Barland, C. O., Zettersten, E., Brown, B. S., Ye, J., Elias, P. M., & Ghadially, R. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22203.x · Cited by 88
Efficacy of S26308 against guinea pig cytomegalovirus infection
Chen, M., Griffith, B. P., Lucia, H. L., & Hsiung, G. D. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.678 · Cited by 84
Berman, B., Sullivan, T. P., Araujo, T. D., & Nadji, M. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05634.x · Cited by 79
Imiquimod in basal cell carcinoma: how does it work?
Dummer, R., Urosevic, M., Kempf, W., Hoek, K. S., Hafner, J., & Burg, G. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05630.x · Cited by 78
Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists
Hengge, U. R., & Ruzicka, T. (2004) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2004.30335.x · Cited by 73
The Immune Response Modifier Resiquimod Mimics CD40-Induced B Cell Activation
Bishop, G. A., Ramirez, L. M., Baccam, M., Busch, L. K., Pederson, L. K., & Tomai, M. A. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1769 · Cited by 68
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis
Vidal, D., Matías‐Guiu, X., & Alomar, A. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06094.x · Cited by 60
Hurwitz, D., Pincus, L. B., & Kupper, T. S. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.10.1347 · Cited by 59
Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic Donors
Frotscher, B., Anton, K., & Worm, M. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.19531.x · Cited by 41
Bottrel, R. L. A., Yang, Y., Levy, D. E., Tomai, M. A., & Reis, L. F. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.856 · Cited by 37
Cited by
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Intratumoral immunotherapy: using the tumor as the remedy
Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx683 · Cited by 375
Arits, A. H., Mosterd, K., Essers, B. A., Spoorenberg, E., Sommer, A., De Rooij, M. J., van Pelt, H. P., Quaedvlieg, P. J., Krekels, G. A., van Neer, P. A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70143-8 · Cited by 312
Miller, L. S. (2008) · Advances in Dermatology · doi:10.1016/j.yadr.2008.09.004 · Cited by 275
Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L., & Kitchener, H. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605611 · Cited by 252
Metadata
- Authors
- Schön, M. P., & Schön, M.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-07
- Volume
- 157
- Pages
- 8-13
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W1846953774
- Cited by
- 346
- References
- 50
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.